Hui Yang

Dr. Hui Yang

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
MZMeijun Zheng
Meijun Zheng
JHJianhan Huang
Jianhan Huang
ATAiping Tong
Aiping Tong
HYHui Yang
Hui Yang
Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration approval, interest in OVs has been boosted greatly. Nevertheless, despite extensive research, oncolytic virotherapy has shown limited efficacy against solid tumors. Recent advances in viral retargeting, genetic editing, viral delivery platforms, tracking strategies, OV-based gene therapy, and combination strategies have the potential to broaden the applications of oncolytic virotherapy in oncology. In this review, we present several insights into the limitations and challenges of oncolytic virotherapy, describe the strategies mentioned above, provide a summary of recent preclinical and clinical trials in the field of oncolytic virotherapy, and highlight the need to optimize current strategies to improve clinical outcomes.

1 April 2020 in Journal of Hospital Infection
Verified
Journal Article
Closed access
DLD. Lu
D. Lu
HWH. Wang
H. Wang
RYR. Yu
R. Yu
HYHui Yang
Hui Yang
YZY. Zhao
Y. Zhao

1 January 2020 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
XTXin Tang
Xin Tang
FLFujun Liu
Fujun Liu
ZLZhiyong Liu
Zhiyong Liu
YCYi Cao
Yi Cao
ZZZongliang Zhang
Zongliang Zhang
LZLiangxue Zhou
Liangxue Zhou
Objective: We conducted a first‐in‐human study to evaluate the bioactivity and safety of B7‐H3‐targeted chimeric antigen receptor (CAR) autologous T cells for treating recurrent anaplastic meningioma.Methods: Tumor tissues from a patient with recurrent anaplastic meningioma were evaluated for B7‐H3 expression. B7‐H3‐targeted CAR‐T cells were delivered into the intracranial tumor resection cavity using an Ommaya device at a maximum dose of 1.5 × 107 cells. Magnetic resonance imaging (MRI) screening and multiple serum indexes were regularly monitored. The patient received surgical intervention after three‐cycle infusions, allowing analysis for CAR‐T‐cell infiltration and target antigen expression in post‐CAR‐T therapy tumor tissues.Results: Immunochemical analysis demonstrated high and homogeneous B7‐H3 expression in tumor samples. MRI results indicated that the tumor near the delivery device was relatively stable compared with the rapid progression of tumors distant from the device. We found CAR‐T‐cell trafficking to regions of B7‐H3+ tumor tissues near the device, but not to tumor tissues distant from the device. Decreased B7‐H3 expression was observed near the region of CAR‐T‐cell infiltration after therapy. The intracavitary delivery of B7‐H3‐targeted CAR‐T cells was well‐tolerated and not associated with any toxic effects of grade 3 or higher.Conclusion: Our results suggested that although intracavitary administration of B7‐H3‐targeted CAR‐T cells was safe and resulted in local bioactivity, addressing antigen loss and CAR‐T‐cell trafficking may further enhance the applications of B7‐H3‐targeted CAR‐T‐cell therapy.

2 October 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
YDYijun Dong
Yijun Dong
ZZZongliang Zhang
Zongliang Zhang
SLSiyuan Luan
Siyuan Luan
MZMeijun Zheng
Meijun Zheng
ZWZeng Wang
Zeng Wang
HYHui Yang
Hui Yang
Background Antibody-drug conjugates (ADCs) offer a promising approach, combining monoclonal antibodies with chemotherapeutic drugs to target cancer cells effectively while minimizing toxicity. Methods This study examined the therapeutic efficacy and potential mechanisms of a bispecific ADC (BsADC) in laryngeal squamous cell carcinoma. This BsADC selectively targets the immune checkpoints programmed cell death ligand-1 (PD-L1) and B7-H3, and the precise delivery of the small-molecule toxin monomethyl auristatin E. Results Our findings demonstrated that the BsADC outperformed its bispecific antibody and PD-L1 or B7-H3 ADC counterparts, particularly in terms of in vitro/in vivo tumor cytotoxicity, demonstrating remarkable immune cytotoxicity. Additionally, we observed potent activation of tumor-specific immunity and significant induction of markers of immunogenic cell death (ICD) and potential endoplasmic reticulum stress. Conclusion In conclusion, this novel BsADC, through immune checkpoint inhibition and promotion of ICD, amplified durable tumor immune cytotoxicity, providing novel insights and potential avenues for future cancer treatments and overcoming resistance.

23 September 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
HWHeng Wei
Heng Wei
ZWZeng Wang
Zeng Wang
YKYi Kuang
Yi Kuang
ZWZhiguo Wu
Zhiguo Wu
SZShasha Zhao
Shasha Zhao
ATAiping Tong
Aiping Tong
Triple-negative breast cancer (TNBC) comprises lethal malignancies with limited treatment options. Chimeric antigen receptor T (CAR-T) cell therapy is an effective immunotherapeutic strategy that has demonstrated unprecedented efficacy in the treatment of hematological malignancies but has shown limited success in the management of some solid tumors. Many malignant tumors are related to increased expression of intercellular adhesion molecule-1 (ICAM1), providing a rationale for ICAM1-specific immunotherapies for the treatment of cancer. Here, we validated the expression of ICAM1 in TNBC tissues. Subsequently, we generated a phage-displayed single-chain variable fragment (scFv) library using splenocytes from ICAM1-immunized mice and selected a novel ICAM1-specific scFv, mG2-scFv. Using mG2-scFv as the extracellular antigen binding domain, we constructed ICAM1-specific CAR-T cells and demonstrated the robust and specific killing of TNBC cell lines in vitro. Most importantly, in the TNBC mouse model, ICAM1-specific CAR-T cells significantly reduced the growth of the TNBC tumor, resulting in long-term remission and improved survival. Together, these results indicated that ICAM1-specific CAR-T cells have high therapeutic potential against ICAM1-positive TNBC tumors.

1 July 2017 in Journal of Voice
Verified
Journal Article
Closed access
DLDan Lu
Dan Lu
BWBei Wen
Bei Wen
HYHui Yang
Hui Yang
FCFei Chen
Fei Chen
Jun LiuJun Liu
Jun Liu
HWHaiyang Wang
Haiyang Wang